Cite
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis
MLA
Daniel H. Ahn, et al. “A Modified Regimen of Biweekly Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Is Both Tolerable and Effective: A Retrospective Analysis.” Therapeutic Advances in Medical Oncology, vol. 9, Feb. 2017. EBSCOhost, https://doi.org/10.1177/1758834016676011.
APA
Daniel H. Ahn, Kavya Krishna, Marlo Blazer, Joshua Reardon, Lai Wei, Christina Wu, Kristen K. Ciombor, Anne M. Noonan, Sameh Mikhail, & Tanios Bekaii-Saab. (2017). A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Therapeutic Advances in Medical Oncology, 9. https://doi.org/10.1177/1758834016676011
Chicago
Daniel H. Ahn, Kavya Krishna, Marlo Blazer, Joshua Reardon, Lai Wei, Christina Wu, Kristen K. Ciombor, Anne M. Noonan, Sameh Mikhail, and Tanios Bekaii-Saab. 2017. “A Modified Regimen of Biweekly Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Is Both Tolerable and Effective: A Retrospective Analysis.” Therapeutic Advances in Medical Oncology 9 (February). doi:10.1177/1758834016676011.